Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7504-7510

  Amato, Robert J ^a   Shingler, William ^b   Naylor, Stuart ^b   Jac, Jaroslaw ^a   Willis, James ^a   Saxena, Somyata ^a   Hernandez McClain, Joan ^a   Harrop, Richard ^b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; MEMBRANE PROTEIN; TROPHOBLASTIC GLYCOPROTEIN 5T4, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKOCYTE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; SKIN NODULE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VACCINATION; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; VACCINIA VIRUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; VACCINATION; VACCINIA VIRUS;

EID: 58149354757     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0668     Document Type: Article

References (16)

1. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006;58:931-47.
2. Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Front Biosci 2006;11:804-17.
3. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-46.
4. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-5.
5. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902.
6. Griffiths RW, Gilham DE, Dangoor A, et al: Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-7.
7. Barrow KM, Ward CM, Rutter J, Ali S, Stern PL. Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn 2005;233:1535-45.
8. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84-92.
9. Eastham AM, Spencer H, Soncin F, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 2007;67:11254-62.
10. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006;12:3416-24.
11. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487-94.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. + T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55:1081-90.
14. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999;17:523-8.
15. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81.
16. Halbert RJ, Figlin RA, Atkins MB, et al. Treatment of patients with metastatic renal cell cancer : a RAND appropriateness panel. Cancer 2006;107:2375-83.